You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

56 search results for: biologics

<b>Biologics</b> in CRSwNP: Comparative Efficacy and Real-World Effectiveness

expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

10 min

Rhinology

Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.

How Can <b>Biologics</b> Improve Lung Function in Pediatric Severe Asthma?

expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

20 min

Pulmonology

Dr. Leonard Bacharier discusses the role of biologics in the improvement of lung function in pediatric severe asthma

Comparative Efficacy of <b>Biologics</b> for Patients with Uncontrolled and/or Severe CRSwNP

expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

7 min

Rhinology

Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.

EAACI 2023 | <b>Biologics</b> in CRSwNP: Comparative Efficacy and Real-World Effectiveness

expert video

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

21 min

Rhinology

Join Profs. Martin Wagenmann and Eugenio De Corso as they discuss type 2 inflammation in CRSwNP and explore real-world data on biologic efficacy.

expert video

UEGW 2024 | Latest Clinical Evidence for Biologics in EoE

11 min

Gastroenterology

Prof. Salvatore Oliva discusses the latest clinical data for EoE that included patients from childhood to adulthood.

ERS 2024 | Can <b>Biologics</b> Affect Airway Remodeling?

expert video

ERS 2024 | Can Biologics Affect Airway Remodeling?

20 min

Pulmonology

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.

expert video

What proportion of patients can achieve control in CRSwNP?

5 min

Rhinology

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.

ERS 2024 | How Can <b>Biologics</b> Help Achieve Clinical Remission in Children With Severe Asthma?

expert video

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

20 min

Pulmonology

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Sharon Dell highlights the available clinical biologic efficacy data in pediatric severe asthma, suggesting the potential for achieving clinical remission when added to an asthma management plan.

expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

2 min

Dermatology

Dr. Amy Paller shares her opinion on practical considerations for evaluating response during treatment with biologics in children with atopic dermatitis.

expert video

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

12 min

Pulmonology

Dr. Francesca Puggioni presents the latest clinical data on achieving on-treatment remission with biologics.

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

2 min

Rhinology

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChileChange country/region